SGLT2 Inhibitors
aka Gliflozins
Key agents Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana)
Class Renal glucose transporter inhibitor / metabolic modulator / gerotherapeutic
Status FDA-approved (diabetes, heart failure, CKD); widely used off-label for metabolic optimization and longevity
TL;DR
SGLT2 inhibitors block renal glucose reabsorption to force ~60–80 g/day urinary glucose loss, creating a continuous fasting-like state: AMPK activation, mTORC1 suppression, ketogenesis, lipolysis. Delivers proven, massive cardio-renal protection (21–38% CV death reduction), renal preservation (~1.5 mL/min/1.73 m²/year eGFR stabilization), favorable body composition (2.5–4.5 kg weight loss, predominantly visceral fat, preserved muscle). Main serious risk: euglycemic DKA (euDKA). Empagliflozin preferred for cardio-renal; Dapagliflozin preferred for heart failure; Canagliflozin carries higher GI and amputation risk and is less favored for off-label use.
Why it matters for Vitals
SGLT2 inhibitors are the most evidence-rich repurposed longevity drug class available. Their wearable biomarker signature includes: lower RHR (1–2 bpm), improved nocturnal HRV (SDNN/RMSSD), reduced nocturnal polyuria with tofogliflozin, and improved OSA AHI via rostral fluid shift reduction. The euDKA risk is the primary safety confound for Vitals users on ketogenic diets or doing fasted training. Body composition preservation of skeletal muscle during weight loss is a differentiator from GLP-1 mono-agonists.
Key Facts
| Mechanism | SGLT2 blockade → renal threshold drops 180–200 → ~40–50 mg/dL → 60–80 g/day glucosuria; downstream: AMPK, mTORC1 suppression, ketogenesis |
| Cardiovascular | 21–38% reduction in CV death/HF hospitalization (EMPA-REG, DAPA-HF, EMPEROR, DELIVER); non-diabetic benefit confirmed |
| Renal | eGFR preservation ~1.5 mL/min/1.73 m²/year vs. placebo; reduced albuminuria; senomorphic tubular cell effects |
| Body composition | 2.5–4.5 kg weight loss (visceral fat); muscle mass preserved; extracellular water loss contributes to early weight drop |
| Wearables | RHR lowering (1–2 bpm); improved nocturnal HRV; tofogliflozin: lowest nocturia burden |
| Dosing (off-label longevity) | Empagliflozin 2.5–5 mg/day (sub-diabetic); Dapagliflozin 10 mg/day; once-daily morning dosing standard |
| Evidence | 10+ large Phase III/IV RCTs; EMPA-REG (n=7000+), CANVAS, DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER, DAPA-CKD, EMPA-KIDNEY |
Mechanism Summary
SGLT2 blockade:
- Lowers renal threshold for glucose from ~180–200 to ~40–50 mg/dL
- Continuous, non-insulin-dependent glucosuria (60–80 g/day ≈ 240–320 kcal/day lost)
Metabolic rewiring:
- ↓ Fasting insulin → removes inhibition on hormone-sensitive lipase → lipolysis
- ↑ Glucagon + ↓ insulin → CPT-1 activation → hepatic fatty acid oxidation
- Excess acetyl-CoA → ketogenesis (↑ BHB)
- ↑ NAD+/NADH ratio → SIRT1 activation → mitochondrial biogenesis
AMPK/mTORC1:
- AMP:ATP ratio rises → AMPK activation → mTORC1 suppression
- Autophagy and mitophagy upregulated; cellular senescence reduced
SGLT selectivity:
| Agent | SGLT2 IC50 (nM) | SGLT1 IC50 (nM) | Selectivity (×) |
|---|---|---|---|
| Empagliflozin | 3.1 | 8300 | ~2700 |
| Dapagliflozin | 1.2 | 1400 | ~1200 |
| Canagliflozin | 2.7 | 710 | ~260 |
Empagliflozin is the most selective; Canagliflozin has meaningful SGLT1 inhibition at higher doses (GI diarrhea risk).
euDKA Risk — Keep Inside This Note
Do not create a separate euDKA note. The risk is intrinsic to the drug class and this hub is the primary retrieval target.
Euglycemic DKA (euDKA): blood glucose < 200 mg/dL with pH < 7.30, bicarbonate < 18 mEq/L, elevated serum ketones. The “euglycemic” presentation is the danger — normal CGM readings mask the acidosis.
Precipitants in non-diabetic users:
- Prolonged fasting or strict ketogenic diet
- Alcohol intoxication
- Intense endurance exercise
- Perioperative states / acute illness
Warning signs: Intractable nausea, vomiting, diffuse abdominal pain, Kussmaul respirations. Discontinue and check ketones immediately if these occur, regardless of CGM reading.
Prevention: Avoid 5-days-on/2-days-off cycling during fasting, ketogenic diets, or intense training blocks.
Cardiovascular Outcomes — Evidence Summary
| Trial | Agent | Population | Key outcome |
|---|---|---|---|
| EMPA-REG OUTCOME | Empagliflozin | T2DM + CVD | 38% CV death reduction |
| DAPA-HF | Dapagliflozin | HFrEF ± diabetes | 26% primary endpoint reduction |
| EMPEROR-Reduced | Empagliflozin | HFrEF | HF hospitalization ↓ 30% |
| DELIVER | Dapagliflozin | HFpEF | 21% composite ↓ |
| DAPA-CKD | Dapagliflozin | CKD ± diabetes | eGFR preservation 1.5 mL/min/yr |
Benefits extend to non-diabetic post-MI patients (EMMY, DAPA-MI, EMPRESS-MI: ~14% all-cause mortality reduction at 12 weeks).
Renal Protection — Evidence Summary
- SGLT2 inhibitors reduce proximal sodium reabsorption → increased distal sodium delivery to macula densa → adenosine release → afferent arteriole constriction → reduced intraglomerular pressure
- Transient eGFR dip in first weeks is benign and protective long-term
- Senomorphic: reduces SA-β-gal activity, SASP factor secretion, and cellular senescence marker gene expression (killifish and human tubular cell data)
- NRF2 activation, GDF15 modulation (kidney aging biomarker)
Body Composition
| Compartment | Effect |
|---|---|
| Visceral fat | Significant reduction — primary driver of metabolic benefit |
| Total fat mass | 2.0–2.6 kg of 2.5–4.5 kg total loss |
| Skeletal muscle | Preserved — not meaningfully reduced |
| Extracellular water | Moderate reduction (diuretic effect) |
| Fat-free mass | Minor reduction (~0.9–1.5 kg) — largely ECW |
Muscle preservation is a key advantage over GLP-1 mono-agonists. Ratio of lean loss to fat loss is favorable compared to semaglutide and tirzepatide.
Dosing Notes for Off-Label Use
| Goal | Strategy |
|---|---|
| Metabolic optimization | Empagliflozin 2.5–5 mg/day (sub-diabetic dose) |
| Longevity/geroprotection | Empagliflozin 5 mg/day or Dapagliflozin 10 mg/day |
| Cycling consideration | 5 days on / 2 days off — preserves mTORC1 anabolism for resistance training; skip off-days during fasted or keto periods |
| Timing | Morning standard; evening may deepen nocturnal ketosis (caution with nocturia — tofogliflozin preferred for evening use) |
Risks and Uncertainty
- euDKA — primary off-label safety concern; mitigated by ketone monitoring, avoiding fasting + drug simultaneously
- Genital mycotic infections — 5–10% incidence; hygiene important
- Orthostatic hypotension / dehydration — especially in first 2–4 weeks
- Canagliflozin: lower-limb amputation signal (CANVAS); higher GI risk at doses ≥ 300 mg
- Fournier’s gangrene — extremely rare but serious; any perineal pain/erythema requires evaluation
- Post-MI data still emerging for purely non-diabetic populations
Links
- Retatrutide — GLP-1 + SGLT2i body composition synergy
- SLU-PP-332 — AMPK/ERR mitochondrial stacking
- GLP-1 GIP Glucagon — incretin overlap; GLP-1 + SGLT2i is foundational longevity stack
- Cardiovascular signatures — HRV/RHR biomarker patterns
- Peptides MOC — stack context
Source: EMPA-REG OUTCOME · CANVAS · DAPA-HF · EMPEROR-Reduced/Preserved · DELIVER · DAPA-CKD · EMPA-KIDNEY · Gemini Deep Research 2026-03-17